Most Comprehensive ADC Conference Dedicated to Asia-Pacific, Where Decision-Makers Gather to Exchange Ideas, Celebrate Excellence, Explore Opportunities, and Drive Business Deals
Key Themes & Topics
Asia’s Leadership in ADC Innovation
Highlighting Asia’s emergence as a global powerhouse in ADC R&D, fueled by biotech innovation, strategic partnerships, and late-stage clinical pipelines.
Next-Generation ADC Discovery & Design
Focus on pioneering novel targeting strategies, linker-payload technologies, and discovery platforms shaping the future of ADCs
Translational Excellence: From Bench to Bedside
Addressing the critical path from preclinical insights to successful clinical outcomes, and emphasizing safety, efficacy, and regulatory considerations.
Manufacturing, CMC & Quality Optimization
Showcasing innovative approaches in Chemistry, Manufacturing, and Controls (CMC), including process efficiency, quality control, and scale-up technologies.
Commercialization, Partnerships & Investment in Asia
Showcasing licensing, partnering, and funding strategies driving growth and commercialization success in the Asian ADC market.
Attendees
Companies
Speakers
The Concept
Asia’s Leading ADC R&D & Manufacturing Conference – Uniting Asia Leaders in Antibody- Drug Conjugates Market
Asia has rapidly emerged as the most dynamic and promising region in the global Antibody-Drug Conjugate (ADC) landscape. With a surge in biotech innovation, multibillion-dollar investments, and strategic partnerships centered around Asian companies, the region is no longer just a rising player—it is setting the pace for the future of ADC development.
From pioneering novel targets to exploring next-generation linker and payload technologies, Asian innovators are reshaping the ADC ecosystem. As clinical programs originating from the region progress into late-stage development, the global industry is closely watching for breakthrough clinical validation that could redefine the therapeutic potential of ADCs.
The ADC Asia Congress 2026 returns to Singapore—bigger, broader, and more influential than ever—as the leading platform for advancing the science, strategy, and success of ADCs in Asia-Pacific. Designed as the most comprehensive ADC conference dedicated to the Asian community, the 2026 edition will bring together 40+ distinguished speakers, global thought leaders, and over 300 industry stakeholders from biopharma, biotech, academia, and regulatory bodies.
Who Should Attend
- VPs & Directors of ADC Early Development, Bioconjugates/Bioconjugation
- VPs & Directors of ADC Manufacturing & Process Development
- VPs & Directors of Novel Modalities R&D, Heads of Toxicology/Pharmacokinetics
- Heads of Translational Medicine and Biology
- WA & WC Professionals
What to Expect
- Latest Breakthroughs in ADC Development and Bioconjugation
- Case Studies on Manufacturing, Process Development, and Translational Medicine
- Insights on QA/QC and Regulatory Challenges
- Networking with Asia's Key ADC Leaders
- Partnership and Collaboration Opportunities
Why it Matters
- Accelerate ADC Innovation from Lab to Clinic
- Overcome Manufacturing and Scalability Hurdles
- Improve targeted Therapy Outcomes
- Build Strategic Connections in Asia's Growing ADC Landscape
Testimonials
“Good speakers and interesting topics.”
EDDC
“Thank you to give us this chance to present our work. We made many connections in the meeting. Gained much more than expected.”
CHO Pharma Inc
“Insightful talks, great networking.”
Singzyme
“Interesting developments with the various start-ups.”
